During the August 30 meeting of the TPSAC Constituents subcommittee , two members raised data quality questions. The Chair, Dr, Samet asked whether the criteria for designating constituents as harmful were replicable; Dr. Lauterbach made a similar comment regarding information being disseminated by the FDA with respect to testing guidance.
The Data Quality Act might well be the only mechanism available to ensure that the FDA does not continue to dominate every facet of the proceeding. To this end, see the CRE statement at the meeting which is attached below.